About Us

Pioneers Who Wrote the Book on
Targeted Protein Degradation

We created IMiDs

Our drug development team is responsible for creating one of the most successful classes of anti-cancer drugs globally, the IMiD franchise of compounds, launched by Celgene. IMiDs (small molecule, cereblon binding “molecular glues), are the only class of clinically-validated protein degrading compounds that are commercially available today.

We are leveraging the discovery of the E3 ligase Cereblon

The identification of cereblon as a key target of the IMiDs validated targeted protein degradation as a drug development strategy with vast commercial potential. We have leveraged our unmatched “molecular glue” experience with the IMiDs in designing the BioTheryX PHM franchise.

Our Protein Homeostatic Modulator PHM® Platform

A Powerful Drug Discovery Engine

Our principal technology platform centers on targeted protein degradation with our PHM® ‘molecular glues’, that enable the design of small molecules to regulate protein equilibrium. Molecular glues can be used to either create a complex of proteins that is more stable by attaching them, giving them better functionality by gluing a diseased protein to a “regulator” protein. This technology utilizes the body’s own protein disposal system to selectively degrade and remove disease-causing proteins. We believe our technology has the potential to address a broad range of disease targets, including those that have to date been considered undruggable.

“This platform is exciting and broad, and can be applied to any substrate. It opens a wide window to the development of novel therapeutic modalities to a broad array of diseases, including malignancies and neurodegenerative disorders.”

Professor Aaron Ciechanover
Nobel Laureate in Chemistry (2004) for the Discovery of Ubiquitin Mediated Protein Degradation

Our Portfolio of High Value Assets in Protein Modulation, Either Targeted Degradation or Regulation to Achieve Homeostasis, Includes:

Leadership

Robert F. Williamson
CEO & PRESIDENT
Bio
Jamie A. Donadio
CHIEF FINANCIAL OFFICER
Bio
Kyle W.H. Chan, Ph.D.
CHIEF TECHNOLOGY OFFICER
Bio
Frank Mercurio, Ph.D.
CHIEF SCIENTIFIC OFFICER
Bio
Dung “Zung” Thai, M.D., Ph.D.
CHIEF MEDICAL OFFICER
Bio
David Stirling, Ph.D.
CHAIRMAN &
FOUNDER OF BIOTHERYX
Bio
Leah Fung, Ph.D.
VICE PRESIDENT OF MEDICINAL CHEMISTRY
Bio
Aparajita Hoskote Chourasia, Ph.D
SENIOR DIRECTOR BIOLOGY
Bio
Lawrence Zaslow
FOUNDER AND SENIOR ADVISOR
Bio

Board of Directors

Louis DeGennaro, Ph.D.
PRESIDENT, CEO OF THE
LEUKEMIA AND LYMPHOMA SOCIETY
Bio
David Stirling, Ph.D.
CHAIRMAN &
FOUNDER OF BIOTHERYX
Bio
Robert F. Williamson
CEO
& PRESIDENT
Bio
Jack Noelke
PRINCIPAL AT
MSD PARTNERS
Bio

Scientific Advisory Board

Yinon Ben-Neriah, M.D., Ph.D.
Bio
Aaron Ciechanover, M.D., D.SC
Bio
David Komander, Ph.D.
Bio
Robert Orlowski, M.D., Ph.D.
Bio
Kevan M. Shokat, Ph.D.
Bio
Peter Walter, Ph.D.
Bio
Brenda Schulman, Ph.D.
Bio

Investors